Glenmark Invites Investment Into Its Independent APIs Unit
Bringing in a minority investor for its Glenmark Life Sciences raw materials unit and divesting non-core products are among the strategic priorities for Glenmark in its current financial year ending in March 2020.
You may also be interested in...
Debt-laden Glenmark Pharmaceuticals has described as “speculative” a report that the firm is discussing with leading Indian family investment office PremjiInvest selling a minority stake in its newly hived-off API subsidiary. The company has promised to remain “proactive” in informing the Bombay Stock Exchange about corporate developments.
Alvogen is claiming the first European launch of a rival to Pierre Fabre’s Navelbine in Europe, through the generics firm’s Lotus Pharmaceuticals subsidiary.
To help fund Phase III clinical trials and US sales and marketing efforts respectively, Glenmark is looking for partners for both its omalizumab biosimilar candidate and its Ryaltris olopatadine and mometasone combination spray.